Associate-Director of Health Innovation Hub
Temerty Faculty of Medicine, University of Toronto
Prof. Paul Santerre
Director of Health Innovation Hub
Temerty Faculty of Medicine, University of Toronto
Mentoring Commercialization and Technology Knowledge for Success in Go-to-Market in Health Care Start-ups
The Health Innovation economy has seen the most rapid ever development, testing, validation, regulatory approval, scale up, and mass distribution of a family of new vaccines by young ventures, partnered with investors and strategic partners. The Health Innovation Hub (H2i) is an early-stage incubator from the Temerty Faculty of Medicine at the University of Toronto. H2i has experienced 7 years of mentoring >250 start-ups in 4-levels, on the above attributes. The companies have garnered over $110M in investment, products/service sales, and non-dilutive funding. This workshop will share the 10 elements of H2i’s successful business canvas, with an emphasis on level 2 and 3 companies.
Is your innovation or business right for venture capital?
Thinking about raising external funding to take your invention or business to the next level. What do Venture Capitalists look for when they evaluate an opportunity? What are some other sources of funding that you could explore? How should you approach the process?
About Michelle McBane:
Michelle is passionate about working with amazing technology entrepreneurs applying disruptive technologies to solve problems in enterprise, health and consumer markets. Michelle is a skilled business professional with many years of combined operational and venture capital experience. Her background includes 16 years of venture capital investing early- and later-stage companies in ICT and Health, managerial and product development experience as well as sales and marketing roles in both engineering and scientific industries. As a Senior Investment Director at the MaRS Investment Accelerator Fund and Managing Director at StandUp Ventures, she leads investments in early-stage companies health and technology companies. Michelle is currently an Observer on the Board of Directors of several companies including Sampler, Matter and Form, tealbook, Bridgit, Maple, Nudge Rewards and OMX. She is also an investor in Figure1 and Rubikloud who have raised substantial follow-on financings. Past exits include Cytochroma (acquired by OPKO) and Locationary (acquired by Apple). She also an Instructor at Ryerson University teaching in the Entrepreneurship stream.Michelle holds a Master of Business Administration (MBA) degree from McMaster University and Bachelor of Applied Science (B.A.Sc.) in Chemical Engineering from the University of Ottawa.
Vice President, Strategic Innovation
It may be clear to you...but, is it clear to others?
Imagine this: The FDA and the EMEA have asked you to meet specific requirements for your study. You need to ensure that you have participants sign an ICF indicating that they understand what they are getting into. Additionally, all participant-facing materials must be reviewed and approved by IRB/ERB before first use. All of this and more needs to be done before enrollment begins in a couple months. The list goes on and on and the amount of medical terminology, acronyms, and legal jargon increases. In the rush to hit important milestones and tick all the boxes to get from trial to market, many skip the important step of considering their audience, the so-what factor and delivering information with context and impact. Ultimately, when it comes to how and what you’re communicating, it may be clear to you; but, is it clear to others?
Your aim is to make advancements in the healthcare space. Yet, without participants, investors, and staff to execute research, how can progress be made? This is where placing value on the power and return of effective communications while conducting clinical research is essential. It is your first opportunity to make a good impression and build trust before going to market. You won’t be able to successfully bridge this gap without informed and committed key stakeholders, so don’t overlook this integral element to success.
Join Daniella McCrorie, Vice President Strategic Innovation with AXON Communications, to learn how to communicate effectively through plain language, empathy, and compelling narratives. You won’t want to miss it!
About Daniella McCrorie:
For over 13 years, Daniella has been driving change within AXON to support clinical trial sponsors in taking a more human and targeted approach to achieve better engagement and education of healthcare practitioners (HCPs), patients and caregivers. Her passion for meaningful communications and better patient care has contributed to the expansion of AXON’s service offerings, including patient insights and application strategies.
Through facilitation of numerous advisory boards with healthcare providers, patients and caregivers, Daniella is empathetic to their experience and maintains this perspective when counseling clients on the best way forward. She has successfully led her teams in the development and implementation of comprehensive global recruitment, retention, and educational programs for clinical trials in various therapeutic areas including neuroscience, cardiology, metabolic, rare disease, and more.
Daniella is a strategic communications expert with a passion for tailoring communications to meet the needs of every target audience. Her proficiency in plain language communication enables her to bring a keen eye to every communications challenge to ensure that context and meaning are being addressed in consideration of the ’so what’ factor.
Daniella graduated from the University of Western Ontario with a BA (Hons.) in English and Sociology.